Herbert Irving Comprehensive Cancer Center
Investigator
Nicole Lamanna, MD
Email
nl2129@cumc.columbia.edu

Nicole Lamanna, MD, is an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia.

She is an experienced clinical investigator and her research focus has been the development of combination therapies that include chemoimmunotherapy, immunomodulatory drugs, novel kinase inhibitors and monoclonal antibodies. She also is working to find active, safer therapies for older patients with these diseases.

She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.


Clinical Studies Managed By This Investigator:
Condition Study Title
Leukemia [ CLOSED ] A study for subjects with chronic lymphocytic leukemia using study drug ABT-199
Leukemia [ CLOSED ] A study for patients with Richter's Transformation (RT) using study drug PNT2258
Leukemia [ CLOSED ] A study for patients Chronic Lymphocytic Leukemia using study drug BI 836826
Leukemia [ CLOSED ] A study for patients with Leukemia using study drug acalabrutinib
Leukemia [ CLOSED ] A study for patients with chronic lymphocytic leukemia (CLL) using study drug TDR-1202
Cancer [ CLOSED ] A study for patients with solid tumors or lymphoma using study drug LY3039478
Cancer [ CLOSED ] Study of Drug in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia [ CLOSED ] Study of Drug in Patients with B-Cell Lymphoid Malignancies
Leukemia [ CLOSED ] Study of Drug in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Leukemia [ CLOSED ] Study of JCAR017 in Subjects with Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia [ CLOSED ] Study of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for Treatment of Chronic Lymphocytic Leukemia
Cancer [ CLOSED ] A Study of MS-553 in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Cancer [ CLOSED ] A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (ALPINE)
Cancer [ CLOSED ] LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkins Lymphoma
Leukemia [ CLOSED ] Study of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia
Leukemia Study of Panzyga in Primary Infection Prophylaxis (Prevention) in Patients with Chronic Lymphocytic Leukemia (PRO-SID)
Leukemia Study of BGB-11417 in Patients with Leukemia
Leukemia Study for Patients with Chronic Lymphocytic Leukemia (CLL) who are Currently Receiving Treatment with Venetoclax
Leukemia Study of Pirtobrutinib (LOXO-305) Alone or in Combination With Chemotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)
Cancer Study of BGB-16673 in Patients with Leukemia or Lymphoma